QUT offers a diverse range of student topics for Honours, Masters and PhD study. Search to find a topic that interests you or propose your own research topic to a prospective QUT supervisor. You may also ask a prospective supervisor to help you identify or refine a research topic.
Found 48 matching student topics
Displaying 13–24 of 48 results
Low-cost portable Magnetic Resonance Imaging for clinical applications
The aim of this project is to develop accurate low-cost medical imaging methodology for pseudo-3D mapping of Mammographic Density (MD) within the breast. MD is the degree of radio-opacity (“whiteness”) in an X-ray mammogram. It has implications for breast cancer risk, ease of detection of breast cancer, and monitoring of the efficacy of hormonal breast cancer prevention or anti-cancer treatments.Healthcare ChallengeThere is a growing need for affordable and accurate quantitative assessment of MD without ionising radiation. Magnetic resonance imaging (MRI) …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Science
- School
- School of Chemistry and Physics
Post-translational modification of proteins in cancer
The Protein Ablation Cancer Therapeutics (PACT) laboratory are interested in understanding how post-translational modifications contribute to the tumorigenic functions of proteins in cancer cells. We hypothesise that particular post-translational modifications are required for the cancer-associated function of a protein and that prevention of these would be a useful approach to treating cancer.The aim of this project is to select a candidate protein from our database of potential targets, confirm the protein is modified, identify the key modified lysine in the …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Developing a precision oncology workflow for Osteosarcoma treatment
Osteosarcoma (OS) is the most common malignant bone tumour that primarily affects children and adolescents. With approximately 400 diagnosed cases/year in Australia, OS has the lowest survival rate of all solid cancers and is the leading cause of cancer-related death in Queensland adolescents. Unfortunately, 3 in 4 patients will not survive longer than five years following diagnosis with metastatic OS. Clinical “one size fits all” treatment strategies results in highly variable and unacceptably poor patient responses. Shockingly, both the OS …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Biomedical Technologies
Characterise a novel DNA repair protein as a target for cancer therapies
Data generated in the lab has identified a novel DNA repair protein previously described as a key protein in HSP70/90 complexes. Many pathways of tumourigenesis are mediated by Heat Shock Proteins and HSP70/90 are found significantly upregulated in ovarian cancers. The targeting of HSP70/90 are an emerging therapeutic avenue for the treatment of ovarian cancer. Supporting this, an inhibitor of HSP90 has been shown to sensitise breast cancer cells to PARP inhibitors and paclitaxel.Our preliminary data indicates that this new …
- Study level
- Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Characterising the role of PARPs in DNA repair and cancer therapy
The genome of our cells is damaged multiple times each day, by various factors including sunlight and reactive oxygen species. In order for the DNA damage response to be efficient, our cells utilise highly coordinated repair pathways that function accurately and rapidly throughout the damaged cell. Cells that do not repair DNA damage correctly will accumulate damage and display increased genomic instability, which is a key hallmark of cancer cells, promoting their survival and rapid growth. DNA repair pathways are …
- Study level
- Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Therapeutic opportunities targeting epigenetic-metabolism crosswalks in cancer
Epigenetic and metabolic pathways in cancer cells are highly interconnected. Epigenetic landscape in cancer cells is modified by oncogene-driven metabolic changes. Metabolites modulate the activities of epigenetic modifying enzymes to regulate the expression of specific genes. Conversely, epigenetic deregulation that occurs in cancer affect the expression of metabolic genes, thereby altering the metabolome. These changes all coordinately enhance cancer cell proliferation, metastasis and therapy resistance.The overall aim of the project is to understand the link between the activity of epigenetic …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Epigenetic regulation of non-coding RNAs in hypoxic tumours
In solid tumours, hypoxia occurs as a result of limitation on oxygen diffusion in avascular primary tumours or their metastases. Persistent hypoxia, significantly reduces the efficacy of radiation and chemotherapy and lead to poor outcomes. This is mainly due to increase in pro-survival genes that suppress apoptosis, enhance tumour angiogenesis, the epithelial-to-mesenchymal transition, invasiveness and metastasis. Much of tumour hypoxia research has been centred on examining the transcriptional targets of hypoxia inducible factors (HIFs).HypothesisEpigenetic changes mediate the effect of hypoxia …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Development of bioengineered 3D tumour models for preclinical breast cancer research
3D organoid model technologies have led to the development of innovative tools for precision medicine in cancer treatment. Yet, the lack of resemblance to native tumours, and the limited ability to test drugs in a high-throughput mode, has limited translation to practice.This project will progress organoid models by using advanced tissue engineering technologies and high-throughput 3D bioprinting to recreate 'mini-tumours-in-a-dish' from a patient’s own tumour cells, and study the effects of various components of the tumour microenvironment on drug response.In …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Biomedical Technologies
Determining the theapeutic efficiency of epigenetic drugs in ovarian cancer
Because cancer and many diseases arise from a combination of genetic propensity and the response of cells to external factors mediated through changes to the expression of key genes, it is important to understand epigenetic regulation. The epigenome is crucial to the changes of gene expression and there is now strong evidence that epigenetic alterations are key drivers of cancer progression. However, very few drugs targeting epigenetic modifiers have been successful, in part due to the lack of effective means …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
PSA splice variant in prostate cancer diagnosis and pathogenesis
Current clinical prostate cancer screening is heavily reliant on measuring serum prostate specific antigen (PSA) levels. However, two-thirds of these men will not have cancer on biopsy and conversely, other prostate diseases. As a result, for ~75% of patients the large number of indolent tumours diagnosed has led to significant overtreatment creating an urgent need for appropriate prognostic assays that can distinguish indolent, slow growing tumours from the more aggressive and lethal phenotypes. PSA/KLK3 is a member of the tissue-kallikrein …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Characterisation of a novel protein co-amplified with the n-MYC oncogene
The MYCN oncogene is amplified in a number of tumour types, including Neuroblastoma (NB) and Neuroendocrine Prostate Cancer (NEPC), where it is associated with worse patient prognosis, as compared to non-amplified tumours. However, the high expression of MYCN (encoding the n-MYC protein) alone in non-amplified tumours is associated with better patient prognosis and less aggressive disease. This suggests that other genes co-expressed in MYCN amplified tumours may be responsible for mediating the aggressive traits of n-MYC. Our team has identified …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Genomics and Personalised Health
Engineering Chimeric Antigen Receptor (CAR) T cell for the treatment of cancer
Chimeric Antigen Receptor (CAR) T cells are genetically modified immune cells that can recognise and kill cancer cells. They do so through the CAR, which recognises specific antigens expressed on cancer cells. CAR T cell therapy has emerged as an effective form of cancer immunotherapy in certain types of blood cancers and are now approved for use in patients. However, CAR T cell therapy can only benefit a very small proportion of cancer patients at present because it is very …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Contact us
If you have questions about the best options for you, the application process, your research topic, finding a supervisor or anything else, get in touch with us today.